NASDAQ:ENTA Enanta Pharmaceuticals (ENTA) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free ENTA Stock Alerts $12.93 +0.17 (+1.33%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$12.76▼$13.1850-Day Range$12.37▼$17.4652-Week Range$8.08▼$28.25Volume156,233 shsAverage Volume243,049 shsMarket Capitalization$273.55 millionP/E RatioN/ADividend YieldN/APrice Target$19.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Enanta Pharmaceuticals alerts: Email Address Enanta Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.17 Rating ScoreUpside/Downside46.9% Upside$19.00 Price TargetShort InterestBearish13.94% of Float Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment-0.02Based on 29 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.90) to ($4.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.26 out of 5 starsMedical Sector314th out of 915 stocksPharmaceutical Preparations Industry135th out of 426 stocks 3.1 Analyst's Opinion Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Enanta Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.94% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 12, which indicates bearish sentiment.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEnanta Pharmaceuticals has received a 73.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Hepatitis medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Enanta Pharmaceuticals is -1.11. Previous Next 1.1 News and Social Media Coverage News SentimentEnanta Pharmaceuticals has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Enanta Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.64% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.99% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enanta Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to grow in the coming year, from ($4.90) to ($4.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Enanta Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaElon Musk Secret Crypto Plot ExposedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Enanta Pharmaceuticals Stock (NASDAQ:ENTA)Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Read More ENTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENTA Stock News HeadlinesMay 10, 2024 | americanbankingnews.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to Post Q1 2025 Earnings of ($1.15) Per Share, HC Wainwright ForecastsMay 10, 2024 | americanbankingnews.comEnanta Pharmaceuticals, Inc. to Post Q3 2024 Earnings of ($1.60) Per Share, Leerink Partnrs Forecasts (NASDAQ:ENTA)May 10, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.May 9, 2024 | americanbankingnews.comEnanta Pharmaceuticals (NASDAQ:ENTA) Upgraded to Hold at StockNews.comMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed: Enanta Pharmaceuticals’ Clinical and Financial Prospects Bolster Investor ConfidenceMay 8, 2024 | finance.yahoo.comEnanta Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 8, 2024 | americanbankingnews.comEnanta Pharmaceuticals (NASDAQ:ENTA) Given New $22.00 Price Target at JMP SecuritiesMay 8, 2024 | americanbankingnews.comEnanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $27.00 by Analysts at HC WainwrightMay 10, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.May 8, 2024 | markets.businessinsider.comHold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial OutlookMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Enanta Pharmaceuticals Amidst Promising RSV Developments and Clinical Trial ExecutionMay 7, 2024 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call TranscriptMay 7, 2024 | businesswire.comEnanta Pharmaceuticals to Participate at the JMP Securities Life Sciences ConferenceMay 7, 2024 | finance.yahoo.comEnanta Pharmaceuticals Inc (ENTA) (Q2 2024) Earnings Call Transcript Highlights: Navigating ...May 7, 2024 | chron.comEnanta Pharmaceuticals: Fiscal Q2 Earnings SnapshotMay 6, 2024 | finance.yahoo.comEnanta Pharmaceuticals Reports Fiscal Q2 Results: A Closer Look Against Analyst ExpectationsMay 6, 2024 | businesswire.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ETMay 5, 2024 | msn.comEnanta Pharma Q2 2024 Earnings PreviewMay 5, 2024 | markets.businessinsider.comEnanta Pharmaceuticals is about to announce its earnings — here's what to expectMay 4, 2024 | americanbankingnews.comEnanta Pharmaceuticals (ENTA) to Release Earnings on MondayMay 3, 2024 | finance.yahoo.comStrong week for Enanta Pharmaceuticals (NASDAQ:ENTA) shareholders doesn't alleviate pain of five-year lossApril 30, 2024 | businesswire.comEnanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 30, 2024 | businesswire.comEnanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal OfficerApril 29, 2024 | businesswire.comEnanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024April 17, 2024 | finance.yahoo.comEnanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024March 19, 2024 | money.usnews.comEnanta Pharmaceuticals IncMarch 13, 2024 | seekingalpha.comENTA Enanta Pharmaceuticals, Inc.See More Headlines Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/20/2023Today5/10/2024Next Earnings (Estimated)8/05/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ENTA CUSIPN/A CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees145Year FoundedN/APrice Target and Rating Average Stock Price Target$19.00 High Stock Price Target$27.00 Low Stock Price Target$11.00 Potential Upside/Downside+46.9%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($6.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-133,820,000.00 Net Margins-187.77% Pretax Margin-184.73% Return on Equity-60.38% Return on Assets-32.29% Debt Debt-to-Equity RatioN/A Current Ratio6.25 Quick Ratio6.25 Sales & Book Value Annual Sales$73.62 million Price / Sales3.72 Cash FlowN/A Price / Cash FlowN/A Book Value$10.29 per share Price / Book1.26Miscellaneous Outstanding Shares21,156,000Free Float18,270,000Market Cap$273.55 million OptionableOptionable Beta0.54 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Jay R. Luly Ph.D. (Age 68)President, CEO & Director Comp: $1.25MMr. Paul J. Mellett Jr. (Age 69)Senior VP of Finance & Administration and CFO Comp: $666.84kDr. Yat Sun Or Ph.D. (Age 72)Senior VP of Research & Development and Chief Scientific Officer Comp: $729.31kMr. Nathaniel S. Gardiner J.D. (Age 70)Consultant Comp: $672.67kMr. Brendan Luu (Age 49)Senior Vice President of Business Development Comp: $622.86kMs. Jennifer VieraSenior Director of Investor Relations & Corporate CommunicationsMore ExecutivesKey CompetitorsCytomX TherapeuticsNASDAQ:CTMXXeris BiopharmaNASDAQ:XERSNektar TherapeuticsNASDAQ:NKTRXBiotechNASDAQ:XBITRAPT TherapeuticsNASDAQ:RAPTView All CompetitorsInsiders & InstitutionsPortland Global Advisors LLCSold 9,800 shares on 5/9/2024Ownership: 0.115%State Board of Administration of Florida Retirement SystemBought 6,781 shares on 5/9/2024Ownership: 0.032%Russell Investments Group Ltd.Sold 4,788 shares on 5/8/2024Ownership: 0.091%SG Americas Securities LLCSold 2,588 shares on 5/7/2024Ownership: 0.036%BNP Paribas Financial MarketsSold 24,776 shares on 5/1/2024Ownership: 0.117%View All Insider TransactionsView All Institutional Transactions ENTA Stock Analysis - Frequently Asked Questions Should I buy or sell Enanta Pharmaceuticals stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ENTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares. View ENTA analyst ratings or view top-rated stocks. What is Enanta Pharmaceuticals' stock price target for 2024? 6 equities research analysts have issued 12 month price objectives for Enanta Pharmaceuticals' shares. Their ENTA share price targets range from $11.00 to $27.00. On average, they anticipate the company's stock price to reach $19.00 in the next twelve months. This suggests a possible upside of 46.9% from the stock's current price. View analysts price targets for ENTA or view top-rated stocks among Wall Street analysts. How have ENTA shares performed in 2024? Enanta Pharmaceuticals' stock was trading at $9.41 at the beginning of the year. Since then, ENTA shares have increased by 37.4% and is now trading at $12.93. View the best growth stocks for 2024 here. When is Enanta Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our ENTA earnings forecast. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its quarterly earnings data on Monday, November, 20th. The biotechnology company reported ($1.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.11) by $0.78. The biotechnology company had revenue of $18.93 million for the quarter, compared to analysts' expectations of $17.93 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 60.38% and a negative net margin of 187.77%. During the same quarter in the previous year, the business posted ($1.27) earnings per share. What ETF holds Enanta Pharmaceuticals' stock? Amplify Treatments, Testing and Advancements ETF holds 4,991 shares of ENTA stock, representing 0.72% of its portfolio. What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO? 5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS). Who are Enanta Pharmaceuticals' major shareholders? Enanta Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BNP Paribas Financial Markets (0.12%), Portland Global Advisors LLC (0.12%), Russell Investments Group Ltd. (0.09%), Hennion & Walsh Asset Management Inc. (0.06%), SG Americas Securities LLC (0.04%) and State Board of Administration of Florida Retirement System (0.03%). Insiders that own company stock include Brendan Luu, Bruce L A Carter, Jay R Luly, Nathalie Adda, Paul J Mellett, Scott T Rottinghaus, Terry Vance and Yat Sun Or. View institutional ownership trends. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ENTA) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICYou need to know these two things about AI stocks ASAP…InvestorPlaceThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.